Last reviewed · How we verify
sIPV+DTaP+HepA
This combination vaccine provides immunization against poliomyelitis, diphtheria, tetanus, pertussis, and hepatitis A through inactivated viral and bacterial antigens.
This combination vaccine provides immunization against poliomyelitis, diphtheria, tetanus, pertussis, and hepatitis A through inactivated viral and bacterial antigens. Used for Prevention of poliomyelitis, Prevention of diphtheria, Prevention of tetanus.
At a glance
| Generic name | sIPV+DTaP+HepA |
|---|---|
| Sponsor | China National Biotec Group Company Limited |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | FDA-approved |
Mechanism of action
sIPV+DTaP+HepA is a pentavalent combination vaccine containing inactivated poliovirus vaccine (sIPV), diphtheria and tetanus toxoids with acellular pertussis vaccine (DTaP), and hepatitis A virus antigen. It stimulates humoral and cellular immune responses to prevent infection by these five pathogens. The vaccine works by presenting antigens that trigger B and T cell responses, leading to production of protective antibodies and memory immunity.
Approved indications
- Prevention of poliomyelitis
- Prevention of diphtheria
- Prevention of tetanus
- Prevention of pertussis
- Prevention of hepatitis A
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sIPV+DTaP+HepA CI brief — competitive landscape report
- sIPV+DTaP+HepA updates RSS · CI watch RSS
- China National Biotec Group Company Limited portfolio CI